Clinical trial NCT05211011: Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection
Official title: Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection (PJI) Caused by Staphylococci, Streptococci, Enterococci and Gram-negative Bacilli, Including Mixed Infections and Culture Negative PJI's ("PROOF-Study")
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Prosthetic Joint Infection
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: Pro-Implant Foundation
First posted: 2022-01-27
Enrollment: 226
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: In this open prospective interventional clinical study patients with hip, knee or shoulder PJI (as defined below) caused by fosfomycin-susceptible staphylococci, streptococci, enterococci or gram-negative bacilli will be included. After inclusion and PJI-surgery, intravenous fosfomycin will be given 5 g every 8 hours for 1, 2, 3-or -4 weeks according to the pathogen and surgery procedure and generally as a part of the antibiotic combination therapy of the treatment algorithm. This Treatment is followed by oral antibiotics for a total of 3 months.
Primary purpose: TREATMENT

Brief summary: The PROOF Study is an open prospective interventional non-randomized study which aim is to determine the outcome / effect and safety of fosfomycin in patients with hip, knee or shoulder PJI.

Detailed description: To confirm a non-inferior effect and the safety of the investigated antimicrobial fosfomycin regimen in PJI of the hip, knee or shoulder against an assumed 80% effect (PJI-free proportion within one year for standard antibiotics aside fosfomycin), following a standardized surgical therapy involving retention, one-stage exchange or two-stage exchange (with short or long interval).

Eligibility criteria: Inclusion Criteria:

1. Informed consent has been obtained (prior to planned surgical PJI treatment);
2. Subject is ≥18 years of age;
3. Subject has either a culture negative or a culture positive PJI of the hip, knee or shoulder prosthesis: (i) visible purulence of a preoperative aspirate or intraoperative periprosthetic tissue (as determined by the surgeon),or (ii) presence of a sinus tract communicating with the prosthesis, or (iii) acute inflammation in intraoperative permanent tissue sections by histopathology (as determined by the pathologist), or (iv) microbial growth in preoperative joint aspirate, intraoperative periprosthetic tissue or sonication fluid of the removed implant (\>50 CFU/ml sonication fluid), or (v) synovial fluid with \>2000 leukocytes/μl or \>70% granulocytes; or reasonable evidence for a suspected PJI (based on clinical, laboratory, and radiological criteria) to undergo joint surgery to proof the PJI diagnosis (according to standard of care, Zimmerli W et al. NEJM 2004);
4. For culture positive PJI's at least one of the following isolates:

   staphylococci (fosfomycin MHK ≤ 32 mg/ml), streptococci (MHK ≤ 128 mg/ml), enterococci (MHK ≤ 128 mg/ml), fosfomycin susceptible gram-negative bacilli, including also mixed infections with other pathogens (fosfomycin susceptible or not);
5. Subject is planned to/will undergo appropriate surgical procedure following the state of the art PJI treatment algorithm, which includes either debridement \& retention of the prosthesis or exchange of the prosthesis. The exchange includes a one-stage exchange, two-stage prosthesis exchange with a short interval (2- 3 weeks) or long interval (6-8 weeks), according to the treatment algorithm;
6. Subject is willing to participate in the study, follow protocol study treatment regimen, and comply with all planned follow-up assessments.

Exclusion Criteria:

1. Allergy or intolerance (or other contraindication) to fosfomycin;
2. Isolation of fungi (molds or yeasts) or mycobacteria;
3. Isolation of one of the following pathogens: staphylococci fosfomycin MHK \> 32 mg/ml, streptococci MHK \> 128 mg/ml, enterococci MHK \> 128 mg/ml , fosfomycin resistant gramnegative bacilli;
4. Severely compromised bone/soft tissue pre or during surgery (if during surgery: exclusion/withdrawalbefore IMP application);
5. Pregnancy, and/or woman wishing to become pregnant;
6. Breast-feeding;
7. Women of childbearing potential without at least one of the following contraception methods: correctly placed coopercontaining or progestin-containing intrauterine device (IUD); female condom used WITH a spermicide (i.e. foam gel, film, cream, or suppository); bilateral tubal ligation/bilateral salpingectomy or bilateral tubal occlusive procedure (at least till the end of the ambulatory treatment phase);
8. Subject has been previously enrolled in this study or was enrolled in another interventional medicinal product or medical device study in the last 30 days;
9. Subject had prior exposure to fosfomycin within the past 4 weeks;
10. Inability to read and understand the participant's information;
11. Subjects institutionalized by warrant or court order;
12. Employees of the sponsor or an involved CRO;
13. In pre surgery culture negative patients: All isolates unsusceptible to fosfomycin after surgery (exclusion / early withdrawal after surgery);
14. Suspected PJI not proven after surgery (exclusion / early withdrawal after surgery).

Primary outcomes:
measure: Infection cure rate
timeFrame: 1 year
Secondary outcomes:
measure: Infection cure rate
timeFrame: 2 years
measure: Proportion of patients with revision
timeFrame: 1 year
measure: Proportion of patients with revision due to hematogenous versus non-hematogenous infection
timeFrame: 1 year
measure: Proportion of patients with unscheduled early revisions
timeFrame: 1 year
measure: Proportion of patients with aseptic revision
timeFrame: 1 year
measure: Proportion of patients with implant failure
timeFrame: 1 year
measure: Proportion of patients with treatment failure
timeFrame: 1 year
measure: Proportion of patients with initially sufficient versus insufficient primary therapy
timeFrame: 1 year
measure: Specific functional joint scores
timeFrame: 1 year
measure: EQ5D5L
timeFrame: 1 year
measure: Safety and tolerability of fosfomycin
timeFrame: 1 year
measure: Peak Plasma Concentration (Cmax)
timeFrame: 1 year
Other outcomes:
Locations:
city: Bochum
country: Germany
facility: BG Universitätsklinikum Bergmannsheil
state: Nordrhein-Westfalen
city: Berlin
country: Germany
facility: Charité
city: Bonn
country: Germany
facility: Universitätsklinikum Bonn
city: Dresden
country: Germany
facility: Städtisches Klinikum Dresden
city: Dresden
country: Germany
facility: Universitätsklinikum Dresden
city: Düsseldorf
country: Germany
facility: Universitätsklinikum Düsseldorf
city: Eisenberg
country: Germany
facility: Waldkrankenhaus Rudolf Elle GmbH
city: Essen
country: Germany
facility: St. Josef Krankenhaus Essen-Werden
city: Hildesheim
country: Germany
facility: Helios Klinikum Hildesheim
city: Köln
country: Germany
facility: Krankenhaus Köln-Merheim
city: Mainz
country: Germany
facility: Universitätsmedizin Mainz
city: Münster
country: Germany
facility: St. Franziskus Hospital Münster
city: Regensburg
country: Germany
facility: Universitätsklinikum Regensburg
city: Weimar
country: Germany
facility: Sophien- und Hufelandklinikum GmbH Weimar
city: Wildeshausen
country: Germany
facility: Krankenhaus Johanneum
city: Wuppertal
country: Germany
facility: Krankenhaus St. Josef
Study officials:
affiliation: Charite University, Berlin, Germany
name: Andrej Trampuz, PD Dr
role: PRINCIPAL_INVESTIGATOR
References: